Eric S. Langer

President and Managing Partner at BioPlan Associates, Inc. He is also the editor of Advances in Biopharmaceutical Technology in India.

Companies often wait for a critical mass before adopting new technologies. But if no one takes the risk, critical mass will never be reached.

New expression systems compete for attention.

With all of the new expressions systems being developed, companies must decide what improved production and yield are really worth.

What will it take for the industry to embrace new hosts?

A closer look at the past year's development in India.

If Indian biologics manufacturers can establish a track record for recombinant products, enhance quality image, maintain cost competitiveness, and demonstrate technology transfer and regulatory knowhow, they are likely to be in the middle of the next boom in biologics manufacturing.

The rapid growth of the pharmaceutical industry in India is yet to create significant changes in the Indian distribution system.

What the Indian government is doing to make its biotech sector as strong as its IT sector.

The bioinformatics industry is currently one of the fastest growing fields in India's biotechnology sector. Indian IT companies have several advantages in the bioinformation field and can continue to grow their opportunities worldwide.